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Fabrication and characterization of DNA-loaded
zein nanospheres
Mary C Regier1†, Jessica D Taylor1†, Tyler Borcyk1, Yiqi Yang1,2 and Angela K Pannier1*
Abstract
Background: Particulates incorporating DNA are promising vehicles for gene delivery, with the ability to protect
DNA and provide for controlled, localized, and sustained release and transfection. Zein, a hydrophobic protein from
corn, is biocompatible and has properties that make it a promising candidate material for particulate delivery,
including its ability to form nanospheres through coacervation and its insolubility under physiological conditions,
making it capable of sustained release of encapsulated compounds. Due to the promise of this natural biomaterial
for drug delivery, the objective of this study was to formulate zein nanospheres encapsulating DNA as the
therapeutic compound, and to characterize size, charge, sustained release, cell cytotoxicity and cellular
internalization of these particles.
Results: Zein nanospheres encapsulating DNA were fabricated using a coacervation technique, without the use of
harsh solvents or temperatures, resulting in the preservation of DNA integrity and particles with diameters that
ranged from 157.8 ± 3.9 nm to 396.8 ± 16.1 nm, depending on zein to DNA ratio. DNA encapsulation efficiencies
were maximized to 65.3 ± 1.9% with a maximum loading of 6.1 ± 0.2 mg DNA/g zein. The spheres protected
encapsulated DNA from DNase I degradation and exhibited sustained plasmid release for at least 7 days, with
minimal burst during the initial phase of release. Zein/DNA nanospheres demonstrated robust biocompatibility,
cellular association, and internalization.
Conclusions: This study represents the first report on the formation of zein particles encapsulating plasmid DNA,
using simple fabrication techniques resulting in preservation of plasmid integrity and tunable sizes. DNA
encapsulation efficiencies were maximized to acceptable levels at higher zein to DNA ratios, while loading was
comparable to that of other hydrophilic compounds encapsulated in zein and that of DNA incorporated into PLGA
nano- and microspheres. The hydrophobic nature of zein resulted in spheres capable of sustained release of
plasmid DNA. Zein particles may be an excellent potential tool for the delivery of DNA with the ability to be
fine-tuned for specific applications including oral gene delivery, intramuscular delivery, and in the fabrication of
tissue engineering scaffolds.
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Background
Gene delivery, the introduction of exogenous DNA into
cells with subsequent expression, is applicable to the
fields of gene therapy [1], DNA vaccination [2], func-
tional genomics and diagnostics [3], and tissue engineer-
ing [4]. Because of the technical and safety issues
associated with viral gene delivery, the use of plasmid
DNA (pDNA), which has lower immunogenicity, more
flexibility in transgene capacity, and has the potential for
industrial production, is an appealing alternative for
gene transfer [5]. Delivery of pDNA can result in the
expression of a therapeutic gene or induction of pro-
tective immunity [2,6]. Although the injection of naked
pDNA can lead to transgene expression, the level and
localization of expression are limited by rapid degrad-
ation by nucleases in the serum and clearance by the
mononuclear phagocyte system [1]. Encapsulation of
pDNA has the potential to improve in vivo response
and transfection by shielding the CpG methylation
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patterns of pDNA from the immune system, shielding the
plasmid from degradation by enzymes and low pH, in-
creasing residence time, and providing a controlled release
[7]. Nano- and microspheres incorporating pDNA, which
administer pDNA in a controlled, sustained, and loca-
lized/targeted manner through the use of polymer systems
that entrap pDNA and release it through hydrolytic or en-
zymatic mechanisms, have been applied to gene therapy,
DNA vaccination, and tissue engineering [7,8].
For gene therapy and DNA vaccination applications,
several routes of administration for DNA delivery sys-
tems are possible, including oral delivery and intramus-
cular injection. The oral route is perhaps the most
appealing, due to its associated high patient compliance
and convenience. The oral route has the additional
advantages of presenting a large surface area of intestinal
epithelium for transfection and allowing treatment of
regional disorders by providing access to the luminal
side of the intestine [9]. Oral gene delivery has the poten-
tial to treat diseases associated with the gastro-intestinal
tract (GI-tract) [10] as well as systemic diseases [11], and
can provide for systemic and mucosal immunity [12].
However, oral delivery of DNA is complicated by low pH
in the stomach and DNases in the GI-tract [13], which
degrade unprotected DNA. Particulates are considered a
viable tool for the protection of DNA from the harsh
environment of the stomach and intestine [14]. Previ-
ous studies have focused on poly(lactide-co-glycolide)
(PLGA) and chitosan to form DNA-loaded nano- and
microspheres for oral gene delivery [7,15-17]. While
these delivery vehicles have been shown to elicit the
production of a therapeutic or immune response indu-
cing protein, the level of protein produced is often
modest with high variability [16,18]. Furthermore, al-
though these materials have provided a valuable proof of
concept, their lack of sufficient efficacy suggests that new
polymers need to be investigated.
The oral route of administration is not the only route
of interest for gene therapy and DNA vaccination. The
direct injection of DNA delivery systems into muscle
has been investigated for DNA vaccination [19] and gene
therapy [20]. Injection of DNA-loaded nanoparticles and
microparticles into muscle primarily results in local
transfection because the particles do not readily diffuse
from the tissue. Transfection of muscle cells can elicit
an immune response [19], can result in a physiological
change in the injected muscle [21], or can serve as a
depot releasing the encoded protein into circulation
[20]. Particulate DNA delivery vehicles have been shown
to increase the magnitude and duration of transgene
expression compared to other delivery vehicles or naked
DNA administered intramuscularly [7,22]. However, as
for oral delivery of DNA-loaded particulates, lack of
sufficient efficacy with intramuscular administration
suggests that new polymers need to be investigated for
DNA delivery.
Natural polymers have been applied to drug and gene
delivery and tissue engineering applications, and have
the advantages of providing innate degradability and bio-
activity [23,24], but typically suffer from low mechanical
properties, poor water stability, limited ability to be pro-
cessed, and a relatively short release period compared to
synthetic polymers [8,25]. However, some natural poly-
mers derived from plants, including wheat gluten, glute-
nin, zein, soy protein, cellulose, and starch [26-28]
overcome some of the shortcomings of natural polymers.
Among the various plant proteins, zein, the prolamin or
storage protein from corn, has properties that make it a
promising candidate material for particulate delivery.
Zein is composed of three fractions, which are defined
by their molecular weight and solubility, including α
(75-85% of total zein, 21–25 kDa and 10 kDa), β (10-
15% of total zein , 17–18 kDa), and γ (5-10% of total
zein, 27 kDa) zein [29]. More than 50% of the 225 amino
acid residues [30] of zein are hydrophobic [31], including
high percentages of leucine, proline, and alanine, which
renders it insoluble under physiological conditions and
capable of sustained release of encapsulated compounds
[32]. Zein also has a high glutamine content [33,34],
contributing polar, protonable side chains. With its
amphiphilic character [35], the hydrophobic regions of
zein can cause aggregation into colloidal particles, and
the polar side chains allow for interaction with DNA.
The surface charge of zein varies with the pH of the en-
vironment [36], with an isoelectric point of α-zein at pH
6.8 [31]. Degradation of zein occurs very slowly by hy-
drolysis but is accelerated by the action of enzymes [32]
and has been shown to be especially well-suited for oral
delivery [37-39]. Zein has been shown to be biocompatible
and to have degradation products that can enhance cell
proliferation [40]. Furthermore, part of the N-terminal
region of γ-zein has been shown to interact with cell
membranes and has served as a peptide carrier for drugs
across cell membranes [41].
Nano- and microspheres composed of zein can be fab-
ricated using a simple coacervation technique, which
involves no harsh solvents or high temperatures. Zein
microparticles have successfully been used to orally de-
liver ivermectin in a canine model [38] and desmopressin
in a Phase I clinical trial [39]. However, to the best of our
knowledge, there have been no reports on the fabrication
of zein nanospheres encapsulating a large, charged and
hydrophilic molecule, like pDNA. Due to the promise of
this natural biomaterial for drug delivery, including its
biocompatibility, promotion of cell proliferation, capabil-
ity for sustained release, interaction with cell membranes,
and its versatility to interact, encapsulate and protect
cargo, the objective of this study was to formulate and
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characterize zein nanospheres encapsulating DNA as the
therapeutic compound, and to perform investigations
into their ability for sustained DNA release, as well as to
characterize cell cytotoxicity and internalization.
Results & discussion
Sphere formation
Coacervation, the separation of solutions into colloidal
systems with two liquid phases [42], was used to form
spheres. This separation involves the formation of one
phase rich in polymer (the coacervate) and another phase
lacking polymer, which is brought about by the partial
desolvation of a previously dissolved polymer [42-44].
Decreasing the ethanol concentration of dissolved zein
solutions by the addition of aqueous solutions results
in the necessary desolvation and the formation of a
zein-rich nanosphere phase [45]. This method has been
previously used to encapsulate a variety of drugs [46-49],
however, to the best of our knowledge, no published
studies have reported on the encapsulation of DNA in
zein. In this current study, pDNA was included with the
aqueous solution added to desolvate zein, which resulted
in the encapsulation of pDNA within the zein nano-
sphere phase formed through coacervation. Encapsula-
tion of hydrophilic pDNA within the hydrophobic zein
spheres was enhanced by lowering the pH of the initial
ethanolic zein solution, which resulted in a net positive
charge on the protein due to its higher isoelectric point
[31]. This change in charge promoted the electrostatic
interaction of the zein and the negatively charged pDNA.
During formation, suspensions of DNA-loaded zein
nanospheres were free of visible aggregates during for-
mation while blank spheres resulted in some visible
aggregates (data not shown). Prior to centrifugation and
collection of the spheres, the pH of the zein nanosphere
suspensions was raised to 10 to lower the surface charge
of the spheres to ~ −70 mV (a value sufficiently far from
zero), resulting in repulsive forces between spheres to
prevent irreversible aggregation of the spheres after cen-
trifugation, and allowing for resuspension of the pelleted
spheres for further analysis and delivery to cells. This
sphere formation, centrifugation, and resuspenison proced-
ure allowed for the simple and repeatable production of
pDNA-loaded nanospheres, which were then characterized.
Characterization
SEM
The morphology and size of the zein/DNA nanospheres
were characterized using SEM. SEM images confirmed
the spherical nature of the nanospheres with smooth
surfaces (Figure 1) at all ratios of zein to pDNA. Average
sizes measured from SEM images were 73.0 ± 0.8 nm
Figure 1 SEM of zein-DNA nanospheres formed at 20:1 (A, 90 k magnification, scale bar 500 nm), 40:1 (B, 90 k, scale bar 500 nm), 80:1
(C, 60 k, scale bar 500 nm), 160:1(D, 60 k, scale bar 500 nm), 250:1 (E, 30 k, scale bar 1 μm) zein:DNA ratios; average diameter for each
ratio measured from SEM images (F), reported as mean ± standard error of the mean.
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(Figure 1A), 95.4 ± 1.0 nm (Figure 1B), 133.2 ± 1.5 nm
(Figure 1C), 196.1 ± 2.6 nm (Figure 1D), and 270 ± 4.5
(Figure 1E) for 20:1, 40:1, 80:1, 160:1 and 250:1 for zein:
DNA spheres, respectively (Figure 1F). The spheres pre-
pared in this study increased in size linearly as the zein
to pDNA ratio increased, but were relatively small com-
pared to zein nanospheres prepared by similar methods,
which have typically been in the 0.5 - 2 μm [48], 0.3
-1.2 μm [49], and 1–1.7 μm [50] range. The smaller size
of the DNA-loaded spheres could be attributed to elec-
trostatic compaction of the particles or as a result of the
precipitation step, when the pDNA may have formed
numerous small particles, which could induce zein to
form many small zein/DNA nanoparticles during coacer-
vation. The increase in sphere size with an increase in
the ratio of zein to incorporated compound has been
reported elsewhere [45]. This increase in sphere size
could be due to a lower mass of pDNA associated with
the surface, which may result in an increase in interfacial
tension between the hydrophobic sphere surface and the
aqueous medium, leading to a greater radius of curva-
ture [45]. These data suggest that the amount of pDNA
present affects the nucleation and growth of zein/DNA
nanospheres and that size can be controlled by adjusting
the zein to pDNA ratio.
DLS
Size and zeta potential were measured to further
characterize and assess the stability of zein/DNA nano-
spheres. Immediately after resuspension, the hydrodynamic
diameters of zein/DNA nanospheres measured in water
increased with increasing zein:DNA ratio for 40:1, 80:1, and
160:1 zein:DNA ratios (157.8 ± 3.9 nm, 266.5 ± 28.2 nm,
and 385.6 ± 25.0 nm, respectively), similar to the trend
observed in SEM images; however no significant differ-
ences in size existed between 20:1 (178.9 ± 10.9 nm) and
40:1 and between 160:1 and 250:1 (396.8 ± 16.1 nm)
ratios for spheres measured by DLS (Figure 2A). The
Figure 2 Size, PdI, and zeta potential for zein/DNA nanospheres formed at various zein to DNA ratios measured directly after
resuspension (0 hours) and three hours after resuspension (3 hours) in wate (A, C, E) or PBS (B, D, F). Data points labeled with the same
letter are not significantly different, while those labeled with asterisks vary significantly (p < 0.05) between the zero hour and 3 hour
measurements. All data are reported as mean ± standard error of the mean, with n = 6.
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average measured diameter from DLS analysis was found
to be greater than the corresponding diameter measured
by SEM for all ratios [51], which may be attributed to the
presence of residual solvent in the spheres that had not
been dried, and/or swelling, which has been reported for
zein fibers in an aqueous medium [52] due to zein’s
hygroscopic character [53]. Zein/DNA nanospheres pre-
pared at zein:DNA ratios of 80:1 or higher were stable in
water over three hours, and the 20:1 and 40:1 zein:DNA
nanospheres exhibited a slight increase in diameter over
the three hours of incubation in water, indicating the
possibility of minimal aggregation at these ratios. In
general PdIs varied between 0.2 and 0.1 demonstrating
uniformity of the spheres (Figure 2C).
Spheres were characterized in PBS to assess the stability
of spheres in a solution with physiological salt concentra-
tion and pH. In this environment, size measurements
above 10 μm (which is beyond the detection limit of the
DLS instrument and thus should not be considered accur-
ate) and PdI values over 0.5 for both 20:1 and 40:1 zein:
DNA spheres align with the observation of aggregation at
these ratios (Figure 2B, D). For 80:1 and higher zein:DNA
ratios, spheres did not aggregate in PBS and measured
sizes were much lower than those of 20:1 and 40:1 parti-
cles in PBS, but were still higher than those measured in
water. These larger sizes, between 740 and 1120 nm, mea-
sured in PBS were attributed to salt induced aggregation
[54], which was subsequently verified by measuring size
and zeta potential and noting the degree of resuspension
and aggregation in solutions with varying salt concentra-
tions (Additional file 1: Figure S1). Spheres formulated at
the higher zein:DNA ratios showed no or little change in
size over three hours in both water and PBS. The zeta
potentials of the spheres formed at the various zein to
DNA ratios were relatively uniform in both water and
PBS, with values distributed between −20 and −50 mV
(Figure 2E, F). Negative values were expected as zein has
an isoelectric point of 6.8 [31] and DNA is also negatively
charged at physiological pH.
Overall, the characteristics of the zein/DNA nano-
spheres formulated in this study suggest that the spheres
could be well-suited for oral administration, particularly
for DNA vaccination, as particles less than 10 μm in
diameter are taken up transparacellularly by Peyer’s
patches in the intestine [55], a target for DNA-encoding
antigens because of their proximity to gut-associated
lymphoid tissue [56]. Stabilization of the 20:1 and 40:1
particles could lend them to oral administration for gene
therapy where widespread transfection is desired or for
intramuscular injection, since particles less than 200 nm
in diameter are taken up by endocytosis [55]. While the
negative surface charge measured for the zein/DNA
spheres may prevent favorable interactions with the nega-
tively charged cell membrane, a negative surface charge
may impart mucoadhesive properties to the particles,
which could increase intestinal residence time [57], fur-
ther enhancing the ability of these particles to be used for
oral administration of DNA therapeutics. In addition,
zein/DNA nanospheres could be used for intramuscular
injection, for DNA vaccination [19], to deliver a thera-
peutic gene targeted to muscle tissue [21], or for systemic
gene therapy [20]. Although the efficacy of the zein/DNA
nanospheres formulated as described in this study could
benefit from stabilization under physiological conditions
and alteration of the surface charge, the spheres have
appropriate size and uniformity for delivery of genes.
Encapsulation & loading
To determine the efficiency of DNA encapsulation for the
method used in this study, percent encapsulation and
loading were measured. Similar to sphere size, encapsula-
tion and loading of DNA in zein nanospheres was
dependent on the ratio of zein to DNA (Figure 3). Per-
cent of DNA encapsulation increased with the ratio of
zein:DNA up to 160:1 where it reached its maximum of
65.3% ± 1.9%. Loading was highest with 6.1 ± 0.2 mg
DNA/g zein for spheres with a zein:DNA ratio of 40:1.
The encapsulation of hydrophilic drugs in zein is more
difficult to achieve than the encapsulation of hydrophobic
drugs presumably due to hydrophilic/hydrophobic inter-
actions. The pDNA loading reported here is typical for
the encapsulation of relatively hydrophilic drugs in zein
nano- and microspheres [47,48] while higher loading (up
to 190 mg drug/g zein) has been attained by conjugating
the hydrophilic drug to zein prior to particle formation
[46]. Furthermore, the pDNA loading achieved in this
study is comparable to that achieved with most PLGA
nano- and microspheres [58], but is much lower than
DNA loading into chitosan/DNA nanoparticles [59,60].
These data indicate that DNA loading can be tailored by
Figure 3 Percent encapsulation and loading of nanospheres
prepared at various zein to DNA ratios. Data labeled with the
same letter are not significantly different. Data are reported as mean
± standard error of the mean, with n = 6.
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changing the zein:DNA ratio, and preliminary results
indicate that increased loading may be produced by
varying the pH and ethanol concentration of the solution
used to dissolve zein (data not shown). Because nano-
spheres formed at a zein to DNA ratio of 80:1 did not
aggregate in PBS and had relatively high encapsulation
efficiency and loading, this ratio was chosen for further
characterization and cell studies.
DNA integrity
DNA integrity is necessary for efficient gene delivery, spe-
cifically maintenance of the supercoiled conformation;
thus integrity measurements were made to ensure that en-
capsulation of the pDNA within the zein spheres did not
damage the pDNA structure. Agarose gel electrophoresis
revealed that pDNA was not damaged by encapsulation
under the conditions used in this study (Figure 4A).
pDNA integrity was also maintained in spheres during
seven days of incubation in PBS for the release studies, as
indicated by a supercoiled to nicked ratio similar to that
of stock pDNA (Figure 4B). Although the nicked band
appears to be larger in release samples than in the stock
pDNA, there does not appear to be an increase in the
ratio of nicked to supercoiled DNA over the seven day
span of the release study (Figure 4C). While the stability
of the pDNA in and released from zein particles is critical
for both oral delivery and intramuscular applications, it
also suggests that these zein/DNA nanospheres could be
used for the fabrication of scaffolds with sustained gene
delivery in tissue engineering [4], in that this stability is
superior to that of pDNA encapsulated in PLGA micro-
spheres, which produce degradation products that lower
the local pH and can degrade pDNA [61]. Finally, the
ability of zein spheres to protect encapsulated pDNA
against nucleases was evaluated with a DNase I assay.
Zein nanospheres showed protection of encapsulated
pDNA from DNase I degradation, with pDNA concen-
trated at the top of the gel and unable to migrate from
the loading well, due to its strong interaction with zein
(Figure 4D). The presence of some degradation products
can be attributed to surface-associated pDNA on the zein
spheres (evident in lane 4), but the majority of the pDNA
remained intact and encapsulated.
Release study
pDNA release from zein nanospheres was measured in a
standard PBS buffer. Nanospheres formulated at the 80:1
zein to DNA ratio released encapsulated pDNA
Figure 4 Agarose gel electrophoresis images of extracted samples for spheres made at various zein to DNA ratios (A): lane 1, ladder;
lane 2, stock DNA; lane 3, 20:1 spheres; lane 4, 20:1 supernatant; lane 5, 40:1 spheres; lane 6, 40:1 supernatant; lane 7, 80:1 spheres;
lane 8, 80:1 supernatant; lane 9, 160:1 spheres; lane 10, 160:1 supernatant; lane 11, 250:1 spheres; lane 12, 250:1 supernatant; lane 13,
stock DNA; lane 14 ladder. Agarose gel image of DNA extracted from spheres (B) and supernatants (C) at various time points in the PBS release
study: lane 1, ladder; lane 2, stock DNA; lane 3, 0 hr; lane 4, 1 hr; lane 5, 3 hr; lane 6, 6 hr; lane 7, 9 hr; lane 8, 12 hr; lane 9, 24 hr; lane 10, ladder;
lane 11, 48 hr; lane 12, 72 hr; lane 13, 96 hr; lane 14, 120 hr; lane 15, 144 hr; lane 16, 168 hr; lane 17, stock DNA; lane 18, ladder. Agarose gel
electrophoresis images of pDNA in DNase I degradation assay : lane 1, ladder; lane 2, stock DNA; lane 3, Naked DNA + DNase I; lane 4, 80:1
spheres + DNase I; lane 5, blank spheres (zein with no DNA); lane 6, 80:1 spheres ; lane 7, stock DNA; lane 8, ladder.
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relatively rapidly for the first 12 hours of the PBS release
study (Figure 5). This period of fast release was followed
by a near zero order release profile for the remainder of
the study. After seven days in PBS only 17.8 ± 0.2% of
the encapsulated pDNA was released. Sustained release
of encapsulated drug in PBS has previously been demon-
strated for zein nano- and microspheres [45,62,63].
These results indicate that if breakdown occurs by hy-
drolysis, it does so slowly, allowing for the release DNA
in a sustained manner over at least one week and likely
much longer, which is critical for intramuscular injection
and tissue engineering applications. For these applica-
tions, sustained release of pDNA over time allows for
transfection to a large number of cells at a localized site
for the enhancement of therapeutic effect [22] or tissue
development [4]. In addition, internalized particles could
provide intracellular sustained release of pDNA. The
observed sustained release for these zein/DNA spheres
also verifies that pDNA is encapsulated within the parti-
cles rather than being absorbed to the surface.
Cell studies
Cell studies were conducted to determine biocompatibil-
ity, cellular association and internalization of the zein/
DNA particles. Biocompatibility of the zein/DNA
spheres with Caco-2 and HEK 293T cell lines was mea-
sured using a WST-1 assay. For HEK 293T cells, absorb-
ance values at a wavelength of 430 nm after 24 hours
only showed statistically significant differences between
cells that were dosed with 2 μg zein/DNA particles and
the control (cell only) condition, but at 48 and 72 hours,
all zein/DNA conditions resulted in absorbance values
that were not statistically significantly different from the
control condition, indicating no cytotoxicity (Figure 6A).
For Caco-2 cells, absorbance values at a wavelength of
430 nm at all times points (24, 48 and 72 hours) showed no statistically significant differences between cells that
were dosed with zein/DNA particles and the control
(cell only) condition, except for two concentrations of
zein/DNA nanoparticles (2 μg and 1 μg of DNA at 48
and 72 hours, respectively), where absorbance values
were significantly increased (p < 0.05) over the control
condition, suggesting an increase in cell proliferation,
similar to previous studies that have shown that the
degradation products of zein can enhance cell prolifera-
tion [40]. For both cell types there was a lack of a dose
response in that the addition of more spheres did not
result in increased cytotoxicity as measured by the
WST-1 assay, indicating that even at high doses the
zein/DNA spheres were biocompatible. In addition,
morphology appeared normal for both cell types incu-
bated with zein/DNA nanospheres (Figure 7 and data
not shown). These results demonstrate that the spheres
in this current study possess biocompatibility with cells.
For confocal imaging, nanospheres were not labeled as
Figure 5 Release of DNA from 80:1 zein spheres incubated in
PBS at 37°C over 7 days. Data reported as mean ± standard error
of the mean, with n = 5.
Figure 6 Cytotoxicity of zein-DNA nanospheres quantified by
WST-1 assay for (A) HEK 293T and (B) Caco-2 cells as a function
of time and DNA dose. Control condition represents cells without
the addition of particles. Data points labeled with the same letter
are not significantly different (p < 0.05). Data reported as
mean ± standard error of the mean, with n = 3.
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zein was observed to autofluoresce at multiple wave-
lengths of excitation and emission. For example, there
was a linear relationship between zein concentration and
fluorescence for excitation wavelengths of 365–395 nm
and 465–485 nm, indicating that zein autofluoresces
under these conditions (Additional file 2: Figure S2).
Confocal images of HEK 293T and Caco-2 cells with
added particles revealed a high degree of particle associ-
ation with both cell types (Figure 7), with no noticeable
changes in cell morphology. Fluorescent nanospheres
were found to concentrate on cells more than in the inter-
cellular spaces of the culture slides, indicating favorable
cell-sphere interactions. To further assess internalization
of the zein nanospheres within the Caco-2 cells, cellular
membranes were stained with Vybrant DiO and then con-
focal imaging was used to visualize both the membrane
and sphere locations (Figure 8). Sphere internalization was
observed in over half of the cells in any particular image
(Figure 8A). Further analysis of individual cells that were
shown to be associated with spheres, through examination
of individual z planes within the plane of the cell, con-
firmed internalization of the spheres. For instance in
Figure 8B, two zein particles in the XZ plane are clearly
internalized, which is further confirmed in the YZ plane.
Punctate green staining within cells is indicative of endo-
somes. While transfection was not observed within the
time course of these internalization studies due to slow
release profile of DNA from the spheres, these results
suggest that DNA/zein nanospheres can enter cells and
thus be used to deliver DNA when properly optimized.
Conclusions
In this work, zein, a natural protein, was investigated as
a possible material for the formation of spheres encapsu-
lating pDNA for gene delivery. Zein is a protein that is
insoluble under physiological conditions, which can
allow for sustained release of encapsulated compounds
and enable zein to act more like a hydrophobic polymer
(i.e. PLGA). Zein is biocompatible and has degradation
products that can enhance cell proliferation [40]. Fur-
thermore, part of the N-terminal region of γ-zein has
been shown to interact with cell membranes and has
served as a peptide carrier for drugs across cell mem-
branes [41]. Zein is commonly used in pharmaceutical
tableting and coating, and is considered most promising
for applications in edible and biodegradable packaging
and coatings as well as biomedical applications [64].
Zein has also shown great potential in the field of drug
delivery [40,65,66], but previous studies have focused on
small molecule, hydrophobic drugs. However, properties
of zein make it well-suited for the development of nonviral
gene delivery systems. Here, zein nanospheres encapsu-
lating DNA were formed using a simple coacervation
method, without the use of harsh solvents or tempera-
tures, resulting in the preservation of pDNA integrity
and tunable sizes. DNA encapsulation efficiencies were
maximized to acceptable levels at higher zein to DNA
ratios, while loading was comparable to that of other
hydrophilic compounds encapsulated in zein and that of
DNA incorporated into PLGA nano- and microspheres.
The spheres were able to protect encapsulated DNA
against degradation by DNAse I, and the hydrophobic
nature of zein resulted in spheres capable of sustained
release of plasmid DNA. Zein-DNA nanospheres showed
Figure 7 Confocal images of HEK 293T cells with associated
fluorescent 80:1 spheres (A, 600X magnification, 0.1 μg
DNA/well) and 250:1 spheres (C, 600X, 0.1 μg DNA/well), and
Caco-2 cells with associated 80:1 spheres (B, 600X, 0.1 μg
DNA/well) and 250:1 spheres (D, 600X, 0.1 μg DNA/well). It
should be noted that not all of the particles fluoresced in the
images as some were out of the focal plane of the microscope.
Scale bars represent 20 μm.
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biocompatibility with cells, and microscopy of cells with
nano/microspheres indicated that the particles were
highly associated with cells and were internalized. Future
work will include modifications to improve cellular up-
take and transfection. Zein appears to be an excellent
potential tool for the delivery of DNA with the ability to
be fine-tuned for specific applications including oral
gene delivery, intramuscular injection, and in the fabri-
cation of tissue engineering scaffolds.
Materials and methods
Plasmid preparation
All experiments used pDsRed2-N1 (Clontech, Mountain
View, CA), a plasmid encoding for the red fluorescent
protein, DsRed2. The plasmid was purified from bacteria
culture using Qiagen (Valencia, CA) reagents and stored
in Tris-EDTA (TE) buffer solution (10 mM Tris, 1 mM
EDTA, pH 7.4) at −20°C. Only plasmids with purity of
1.8 or better measured by 260/280 ratio (Nanodrop 2000
Spectrophotometer, Thermo Scientific, Waltham, MA)
were used.
Sphere preparation
Zein spheres were formed by the coacervation tech-
nique. Zein (Freeman Industries LLC, Tuckahoe, New
York) was first dissolved in 70% ethanol at pH 3 (pH
adjusted with 1 M hydrochloric acid) forming a 1% w/v
zein solution. Subsequently, 1 mL of 100% ethanol pH 3
was added to 1 mL of the 1% zein solution. A total of
1 mL of DsRed2 plasmid DNA (1 mg/mL in TE buffer)
and TE buffer were added, followed by the dropwise
addition of 10 mL ddH2O (18.2 mΩ-cm) while vortex-
ing. Spheres were formed by coacervation during the
addition of the ddH2O. The zein to DNA ratio was
determined by the amount of DNA solution added and
ranged from 20:1 to 250:1. Blank spheres were formed
without DNA (TE buffer substituted for DNA solution).
The pH of the resultant sphere suspension was increased
to 10 by the addition of 1 M NaOH so that the spheres
could be resuspended, as this pH induced sufficient sur-
face charge on the spheres to prevent aggregation during
centrifugation [67-69]. Spheres were then pelleted by
centrifugation at 10,000 g for 1 hour at room temperature.
The supernatant was removed and spheres were resus-
pended in ddH2O.
Sphere characterization
Field-emission scanning electron microscopy
Scanning electron microscopy (SEM, S4700 Field-
Emission SEM, Hitachi, Japan) was used to image and
subsequently analyze sphere size and morphology. For
SEM imaging, spheres were resuspended in 2 mL of
ddH2O and lyophilized. The lyophilized powder was
placed in a thin layer on carbon tape (Electron Micros-
copy Sciences, Hatfield, PA) and mounted for imaging.
Spheres were then sputter coated with chromium and
imaged at 10 kV and varying magnifications. Three micro-
graphs for each ratio were analyzed using Image J (NIH,
Bethesda, MD) to determine average sphere diameter.
Dynamic light scattering
A dynamic light scattering (DLS) analyzer (Zetasizer
Nano ZS90, Malvern Instruments Ltd, UK) was used to
measure the mean diameter and particle size distribution
of spheres after dilution in either 1X Dulbecco’s phos-
phate buffered saline (PBS, Invitrogen, Carlsbad, CA) or
ddH2O. For dilution in PBS, spheres were first resus-
pended in 2 mL of water and then diluted further with
Figure 8 Analysis of sphere internalization within Caco-2 cells, with DiO membrane staining, using merged fluorescence confocal
images of entire z-stack with orthogonal views, XZ and YZ (A) and a digital magnification of the area outlined by a white square in A
(B). Punctate green staining within cells are indicative of endosomes. Filled arrows indicate internalized, autofluorescent nanospheres. Scale bars
in A and B represent 50 and 20 μm, respectively.
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1X PBS due to the inability of spheres to initially be
completely resuspended in PBS. Intensity mean diameter
was used to express average particle size. The same in-
strument was used to measure the zeta potential of the
spheres by a combination of laser Doppler velocimetry
and phase analysis light scattering. Sphere suspensions
above were likewise diluted in 1X PBS or ddH2O before
measurement. Size, zeta potential and the polydispersity
index (PdI) were measured directly after resuspension
and 3 hours after resuspension for each sample to assess
stability. To determine the cause of aggregation of the
spheres in PBS and the inability of pelleted spheres to be
resuspended in PBS, sphere size and zeta potential were
similarly measured at various salt concentrations. The
spheres were resuspended and diluted in 1X PBS or
ddH2O with NaCl concentrations of 300, 150, 50 and
10 mM. Size and zeta potential were measured before
centrifugation and again after centrifugation and resus-
pension. The degree of resuspension was noted for all
conditions.
Encapsulation & loading
pDNA encapsulation within the spheres was quantified
using a standard phenol/chloroform extraction followed
by fluorescent staining with Hoechst 33258 (Invitrogen).
After sphere preparation and centrifugation, the super-
natant was removed to a separate conical tube and pel-
leted spheres were resuspended in 5 mL ddH2O. An
equal volume of phenol/chloroform/isoamyl alcohol
25:24:1 (Fisher BioReagents, Fair Lawn, NJ) was added
to both the sphere and the supernatant solutions and
these solutions were vortexed. The solutions were cen-
trifuged at 10,000 g for 15 minutes at 4°C and then the
top, aqueous layer was removed to separate tubes, to
which 0.5 volume of chloroform (Fisher Chemical, Fair
Lawn, NJ) was added, followed by vortexing. Solutions
were again centrifuged at 10,000 g for 15 minutes at 4°C
and the top, aqueous layer was then removed to separate
tubes, which were centrifuged at 10,000 g for 15 minutes
at 4°C to separate any residual chloroform from the
aqueous layer. Any organic layer present was removed
from the bottom of the tubes. The volumes of the aque-
ous DNA solutions were measured. Samples extracted
from spheres and supernatants were then diluted appro-
priately in 1X TNE buffer (10 mM Tris; 0.2 M NaCl;
1 mM EDTA; pH 7.4), mixed with one volume Hoechst
dye solution (200 ng/mL) and fluorescence was measured
by a fluorometer (Modulus Luminometer/Fluorometer,
Turner Biosystems, Sunnyvale, CA) after 5 minutes incu-
bation at room temperature. A Hoechst standard curve
was produced by graphing raw fluorescence versus DNA
concentration for various dilutions of the stock DNA so-
lution. The standard curve was then used to quantify the
amount of DNA in the sphere and supernatant extraction
solutions, using fluorescence measurements that were
first normalized to the fluorescence of blank sphere ex-
traction solutions. The mass balance for DNA was closed
between 80% and 101% as measured by recovery:
Percent encapsulation was calculated as:
Percent Encapsulation
¼ Mass of DNA in Sphere Extract
Mass of DNA Added
 100% ð2Þ
For each sphere preparation ratio of zein to DNA, the
mass of DNA in spheres per mass of spheres was calcu-
lated, using measurements of DNA encapsulation
described above and mass of lyophilized spheres for each
ratio, as:
Loading ¼ Mass of DNA in Sphere Extract ðmgÞ
Mass of Spheres ðgÞ
ð3Þ
DNA integrity
Sphere extraction solutions and release samples (as
described below) were analyzed for plasmid integrity, as
was the ability of the spheres to protect encapsulated
pDNA from endonucleases. For the latter, naked pDNA
(10 μg) and DNA-loaded zein spheres (equivalent to
10 μg of pDNA) were treated with 7.5 U of DNase I (Pro-
mega, Madison, WI) and incubated for 15 min at 37°C.
The reaction was stopped by adding 50 mM Ethylenedia-
minetetraacetic acid (EDTA) and incubating at 65°C for
10 min. The integrity of the pDNA was analyzed by agar-
ose (1%) gel electrophoresis. DNA was detected using
ethidium bromide (Fisher BioReagents). A Kodak gel
documentation system (EDAS 290, Kodak, Rochester,
NY) was used to capture digital images of the gels.
Release study
For release studies, pelleted spheres were resuspended in
2 mL ddH2O. Separate samples for each time point were
prepared by diluting 150 μL of sphere suspension (con-
taining approximately 750 μg of zein and 4.3 μg of
Recovery ¼ Mass of DNA in Sphere ExtractþMass of DNA in Supernatant Extract
Mass of DNA Added
 100% ð1Þ
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DNA) in 3 mL of release media. These samples were incu-
bated in a humidified 37°C chamber for varying times. At
predetermined time points, an entire sample was removed
from the incubator and spheres were separated from the
supernatant by centrifugation. The spheres and the
supernatant were extracted with phenol/chloroform and
DNA was quantified by Hoechst assay, both as described
above.
DNA release from spheres into 1X PBS was measured
over 7 days. Samples for loaded and blank spheres were
centrifuged at 0, 1, 3, 6, 9, 12, 24, 48, 72, 96, 120, 144,
and 168 hours. At each time point, samples were centri-
fuged at 10,000 g for 30 minutes at room temperature to
separate spheres from the supernatant and analyzed as
described above. Release was calculated:
PBS Release
¼Mass of DNA in Supernatant at Time ¼ tð Þ
Total Mass of DNA at Time ¼ 0ð Þ 100%
ð4Þ
Cellular response
Cell culture
Human embryonic epithelial kidney cells, HEK 293T
(ATCC, Manassas, VA), were cultured in T-75 flasks in
Dulbecco’s modified Eagle’s medium (DMEM, Gibco/
Invitrogen, Carlsbad, CA) containing 4.5 g/L glucose
and supplemented with 10% fetal bovine serum (FBS,
Gibco), 2 mM L-glutamine (Gibco), and 1% penicillin/
streptomycin (Gibco). For seeding, cells were counted
using a hemocytometer and trypan blue staining for viable
cells after being dissociated with 1 mM EDTA. Human
colon carcinoma cells, Caco-2, were obtained from ATCC
and were cultured in T-75 flasks in Eagle’s minimum
essential medium (EMEM, ATCC) supplemented with
20% FBS (Gibco) and 1% penicillin/streptomycin (Gibco).
For seeding, cells were dissociated with 0.05% trypsin/
EDTA (Gibco). For both cell lines, cells were seeded into
48-well plates or 8-well Nunc Lab-Tek chambered cover-
glass slides (Thermo Scientific) at a density of 30,000-
33,000 cells per well for HEK 293T cells and 25,000 cells
per well for Caco-2 cells.
Cytotoxicity
Cytotoxicity was assessed using a Water Soluble Tetra-
zolium (WST-1) salts cell proliferation assay kit (Roche,
Indianapolis, IN). For the WST-1 assay, nanospheres
containing 0.1, 0.25, 0.5, 1.0 or 2.0 μg of DNA were
formed at a zein to DNA ratio of 80:1, resuspended in
1 mL ddH2O, and then diluted in OptiMem (Gibco) to a
final volume of 75 μL. Cells were seeded in 48-well
plates as described above and after 24 hours of culture,
zein/DNA nanospheres were added to the culture media
in triplicate wells. Cells were imaged to observe cell
morphology (Leica DMI 3000B, Bannockburn, IL) and
the WST-1 assay was conducted according to the
manufacturer’s protocol at 24, 48, and 72 hours after
the addition of zein nanospheres. Briefly, cells were
washed with PBS, and incubated at 37°C with the WST-1
solution (10 vol.% WST-1 reagent in phenol-free DMEM,
400 μl /well). After incubation for 3 hours, absorbance
values of WST-1 solution (100 μl from each well) were
measured on an Epoch Microplate spectrophotometer
(BioTek, Winooski, VT) at a wavelength of 430 nm.
Assays were performed in triplicate on duplicate days.
Confocal microscopy
To verify that confocal microscopy could be used to image
zein/DNA nanospheres without labeling, the autofluores-
cence of zein was investigated. The autofluorescence of
various zein concentrations in 70% ethanol was measured
in a fluorometer with ultraviolet and blue modules. Once
autofluorescence was confirmed, confocal microscopy was
used to assess cellular morphology in response to the zein
nanospheres, as well as to analyze cellular association of
the spheres. Caco-2 and HEK 293T cells cultured with
80:1 or 250:1 nanospheres were imaged using a confocal
microscope (Olympus IX 81, Olympus, Center Valley,
PA). Cells were seeded as described above into 8-well
coverslides. Zein spheres were visualized with an excita-
tion wavelength of (405 nm) and an emission wavelength
of (590 nm) and these images were overlaid with corre-
sponding phase images.
Sphere internalization
To assess internalization of zein nanospheres, Caco-2
cells were seeded onto 8-well coverslides described
above and after 36 hours of culture, media was replaced
and zein/DNA nanospheres containing 0.1 μg DNA at
a zein to DNA ratio of 80:1 were added to the fresh cul-
ture media. Twelve hours after the media change and
addition of spheres, the cells were washed and then
stained using Vybrant DiO cell-labeling solution (Mo-
lecular Probes/Life Technologies, Carlsbad, CA) for 25
minutes at 37° C according to the manufacturer’s proto-
col. Cells were then washed with PBS and fixed with
10% buffered formalin for 10 minutes. Following stain-
ing, confocal microscopy was performed, with zein and
DiO sequentially excited using dual excitation of 405
and 543 nm for zein and 488 nm for DiO. A series of
15 optical sections in the Z-plane were acquired at inter-
vals of 1 μm for at least two different locations per well
and images were processed using Olympus FluoView
software (v.5.0) to determine location of the spheres
relative to cellular membranes.
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Statistics
All experiments were performed between three and six
times (noted in figure legends). Comparative analyses
were completed using a student’s t-test or one-way
ANOVA followed by Tukey’s multiple comparison test
for multiple data points, both at a 95% confidence level
using Prism software (GraphPad Prism 5, LaJolla, CA).
Mean values with standard error of the mean are
reported for all data.
Additional files
Additional file 1: Figure S1. Size, PdI, and zeta potential for
nanospheres resuspended at various salt concentrations (A, B, C
respectively), formed at 80:1 zein to DNA ratio. One hour data labeled
with the same letter do not vary significantly while asterisks in the
legend denote a significant difference (p < 0.05) between zero and one
hour measurements. All data are reported as mean ± standard error of
the mean, with n = 3.
Additional file 2: Figure S2. Autofluorescence of zein at various
concentrations using ultraviolet (365–395 nm) and blue
(465–485 nm) modules.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MCR participated in design of the study and carried out all studies on
encapsulation, size, and release and drafted the manuscript. JDT carried out
the cytotoxicity, DNase I protection assays, internalization studies and
assisted in manuscript preparation and editing. TB carried out a portion of
the DLS studies. YY participated in the design of the study. AKP conceived of
the study, and participated in its design and coordination and helped to
draft the manuscript. All authors read and approved the final manuscript.
Acknowledgements
Support for this research was provided in part by funds from the American
Heart Association, the University of Nebraska Foundation (Layman Funds),
the Nebraska Research Initiative, USDA CSREES-Nebraska (NEB-21-146), and
the Institute of Agriculture and Natural Resources Seed Grant Program.
Confocal and scanning electron microscopy were performed at the
University of Nebraska-Lincoln’s Center for Biotechnology Morrison
Microscopy Core Research Facility and we thank Dr. You Zhou and Dr. Han
Chen for assistance with imaging. We thank Dr. Shannon Bartelt-Hunt for the
use of the Zetasizer, Dr. Curtis Weller for the use of the lyophilizer, Tadas
Kasputis, Tim Martin, Sarah Plautz, and Dr. Qiuran Jiang for assistance with
cell studies and Dr. Zhongji Han for imaging gels.
Author details
1Department of Biological Systems Engineering, University of
Nebraska-Lincoln, 231 Chase Hall, Lincoln, NE 68583-0726, USA. 2Department
of Textiles, Clothing and Design, University of Nebraska-Lincoln, 231 Chase
Hall, Lincoln, NE 68583-0726, USA.
Received: 7 June 2012 Accepted: 27 November 2012
Published: 2 December 2012
References
1. Niidome T, Huang L: Gene therapy progress and prospects: Nonviral
vectors. Gene Ther 2002, 9:1647–1652.
2. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA: DNA vaccines. Annu Rev Immunol
1997, 15:617–648.
3. Pannier AK, Ariazi EA, Bellis AD, Bengali Z, Jordan VC, Shea LD:
Bioluminescence imaging for assessment and normalization in
transfected cell arrays. Biotechnol Bioeng 2007, 98:486–497.
4. Shea LD, Smiley E, Bonadio J, Mooney DJ: DNA delivery from polymer
matrices for tissue engineering. Nat Biotechnol 1999, 17:551–554.
5. Mintzer MA, Simanek EE: Nonviral vectors for gene delivery. Chem Rev
2009, 109:259–302.
6. Li S, Huang L: Nonviral gene therapy: promises and challenges. Gene Ther
2000, 7:31–34.
7. Agarwal A, Mallapragada SK: Synthetic sustained gene delivery systems.
Curr Top Med Chem 2008, 8:311–330.
8. Panyam J, Labhasetwar V: Biodegradable nanoparticles for drug and gene
delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329–347.
9. Bhavsar MD, Amiji MM: Gastrointestinal distribution and in vivo gene
transfection studies with nanoparticles-in-microsphere oral system
(NiMOS). J Control Release 2007, 119:339–348.
10. Page DT, Cudmore S: Innovations in oral gene delivery: challenges and
potentials. Drug Discov Today 2001, 6:92–101.
11. Rothman S, Tseng H, Goldfine I: Oral gene therapy: A novel method for
the manufacture and delivery of protein drugs. Diabetes Technol Ther
2005, 7:549–557.
12. Jones DH, Corris S, McDonald S, Clegg JC, Farrar GH: Poly(DL-lactide-co-
glycolide)-encapsulated plasmid DNA elicits systemic and mucosal
antibody responses to encoded protein after oral administration.
Vaccine 1997, 15:814–817.
13. Loretz B, Foger F, Werle M, Bernkop-Schnurch A: Oral gene delivery:
Strategies to improve stability of pDNA towards intestinal digestion.
J Drug Target 2006, 14:311–319.
14. Chen H, Langer R: Oral particulate delivery: status and future trends.
Adv Drug Deliv Rev 1998, 24:339–350.
15. Roy K, Mao H-Q, Huang S-K, Leong KW: Oral gene delivery with
chitosan-DNA nanoparticles generates immunologic protection in a
murine model of peanut allergy. Nat Med 1999, 5:387–391.
16. Bowman K, Sarkar R, Raut S, Leong KW: Gene transfer to hemophilia A
mice via oral delivery of FVIII-chitosan nanoparticles. J Control Release
2008, 132:252–259.
17. Jones DH, Clegg JC, Farrar GH: Oral delivery of micro-encapsulated DNA
vaccines. Dev Biol Stand 1998, 92:149–155.
18. He X-W, Wang F, Jiang L, Li J, Liu S-K, Xiao Z-Y, Jin X-Q, Zhang Y-N, He Y, Li
K, et al: Induction of mucosal and systemic immune response by single-
dose oral immunization with biodegradable microparticles containing
DNA encoding HBsAg. J Gen Virol 2005, 86:601–610.
19. O'Hagan DT, Singh M, Ulmer JB: Microparticles for the delivery of DNA
vaccines. Immunol Rev 2004, 199:191–200.
20. Tripathy SK, Svensson EC, Black HB, Goldwasser E, Margalith M, Hobart PM,
Leiden JM: Long-term expression of erythropoietin in the systemic
circulation of mice after intramuscular injection of a plasmid DNA
vector. Proc Natl Acad Sci USA 1996, 93:10876–10880.
21. Shyu K-G, Manor O, Magner M, Yancopoulos GD, Isner JM: Direct
intramuscular injection of plasmid DNA encoding angiopoietin-1 but not
angiopoietin-2 augments revascularization in the rabbit ischemic
hindlimb. Circulation 1998, 98:2081–2087.
22. Wang J, Zhang P-C, Mao H-Q, Leong KW: Enhanced gene expression in
mouse muscle by sustained release of plasmid DNA using PPE-EA as a
carrier. Gene Ther 2002, 9:1254–1261.
23. Dang JM, Leong KW: Natural polymers for gene delivery and tissue
engineering. Adv Drug Deliv Rev 2006, 58:487–499.
24. Malafaya PB, Silva GA, Reis RL: Natural-origin polymers as carriers and
scaffolds for biomolecules and cell delivery in tissue engineering
applications. Adv Drug Deliv Rev 2007, 59:207–233.
25. Yannas IV: Natural Materials. In Biomaterial Science: An Introduction to
Materials in Medicine. 2nd edition. Edited by Ratner BD, Hoffman AS, Schoen
FJ, Lemons JE. San Diego: Academic Press; 2004.
26. Czaja WK, Young DJ, Kawecki M, Brown RM Jr: The future prospects of
microbial cellulose in biomedical applications. Biomacromolecules 2007,
8:1–12.
27. Malafaya PB, Stappers F, Reis RL: Starch-based microspheres produced by
emulsion crosslinking with a potential media dependent responsive
behavior to be used as drug delivery carriers. J Mater Sci Mater Med 2006,
17:371–377.
28. Reddy N, Yang Y: Potential of plant proteins for medical applications.
Trends Biotechnol 2011, 29:490–498.
29. Esen A: A proposed nomenclature for the alcohol-soluble proteins (zeins)
of maize (Zea mays L.). Journal of Cereal Science 1987, 5:117–128.
Regier et al. Journal of Nanobiotechnology 2012, 10:44 Page 12 of 13
http://www.jnanobiotechnology.com/content/10/1/44
30. Geraghty D, Peifer MA, Rubenstein I, Messing J: The primary structure of a
plant storage protein: zein. Nucleic Acids Res 1981, 9:5163–5174.
31. Cabra V, Arregun R, Galvez A, Quirasco M, Vazquez-Duhalt R, Farres A:
Characterization of 19 kDa alpha-zein of high purity. J Agric Food Chem
2005, 53.
32. Hurtado-Lopez P, Murdan S: Zein microspheres as drug/antigen carriers: A
study of their degradation and erosion, in the presence and absence of
enzymes. J Microencapsul 2006, 23:303–314.
33. Pomes AF: Zein. In Encyclopedia of Polymer Science and Technology: plastics,
resins, rubbers, fibers vol. 15. Edited by Mark HF, Gaylord NG, Bikales NM.
New York: Interscience Publishers; 1971:125–132.
34. Padua GW, Wang Q: Controlled Self-Organization of Zein Nanostructures
for Encapsulation of Food Ingredients. In Micro/Nanoencapsulation of
Active Food Ingredients. Edited by Huang Q, Given P, Qian M. Washington D.
C: American Chemical Society; 2009:143–156.
35. Wang Q, Wang JF, Geil PH, Padua GW: Zein adsorption to hydrophilic and
hydrophobic surfaces investigated by surface plasmon resonance.
Biomacromolecules 2004, 5:1356–1361.
36. Deo N, Jockusch S, Turro NJ, Somasundaran P: Surfactant interactions with
zein protein. Langmuir 2003, 19:5083–5088.
37. Parris N, Cooke PH, Hicks KB: Encapsulation of essential oils in zein
nanospherical particles. J Agric Food Chem 2005, 53:4788–4792.
38. Gong S-J, Sun S-X, Sun Q-S, Wang J-Y, Liu X-M, Liu G-Y: Tablets based on
compressed zein microspheres for sustained oral administration: Design,
pharmacokinetics and clinical study. J Biomater Appl 2010, 00:1–14.
39. DiBiase MD, Morrel EM: Oral Delivery of Microencapsulated Proteins. In
Protein Delivery: Physical Systems. Volume 10. Edited by Sanders LM, Hendren
RW. New York: Plenum Press; 1997 [Borchardt RT (Series Editor):
Pharmaceutical Biotechnology].
40. Sun Q-S, Dong J, Lin Z-X, Yang B, Wang J-Y: Comparison of
cytocompatibility of zein film and other biomaterials and its
degradability in vitro. Biopolymers 2005, 78:268–274.
41. Fernandez-Carneado J, Kogan MJ, Castel S, Giralt E: Potential peptide
carriers: amphipathic proline-rich peptides derived from the N-terminal
domain of gamma-zein. Angew Chem Int Ed Engl 2004, 43:1811–1814.
42. Gander B, Blanco-Prieto MJ, Thomasin C, Wandrey C, Hunkeler D:
Coacervation and Phase Separation. In Encyclopedia of Pharmaceutical
Technology, vol. 1. New York: Informa; 2006.
43. Madan PL: Microencapsulation I. Phase separation or coacervation.
Drug Dev Ind Pharm 1978, 4:95–116.
44. Arshady R: Microspheres and microcapsules, a survey of manufacturing
techniques Part II: Coacervation. Polym Eng Sci 1990, 30:905–914.
45. Hurtado-Lopez P, Murdan S: Formulation and characterisation of zein
microspheres as delivery vehicles. J Drug Deliv Sci Tech 2005, 15:267–272.
46. Suzuki T, Sato E, Matsuda T, Tada H, Unno K, Kato T: Preparation of zein
microspheres conjugated with antitumor drugs available for selective
cancer chemotherapy and development of a simple colorimetric
determination of drugs in microspheres. Chem Pharm Bull 1989,
37:1051–1054.
47. Wang H-J, Lin Z-X, Liu X-M, Sheng S-Y, Wang J-Y: Heparin-loaded zein
microsphere film and hemocompatibility. J Control Release 2005,
105:120–131.
48. Fu J-X, Wang H-J, Zhou Y-Q, Wang J-Y: Antibacterial activity of
ciprofloacin-loaded zein microsphere films. Material Science and
Engineering C 2009, 29:1161–1166.
49. Liu X, Sun Q, Wang H, Zhang L, Wang J: Microspheres of corn protein,
zein for an invermectin drug delivery system. Biomaterials 2005,
26:109–115.
50. Muthuselvi L, Dhathathreyan A: Simple coacervates of zein to encapsulate
gitoxin. Colloids and Surfaces B: Bioinformatics 2006, 51:39–43.
51. Zhong Q, Jin M: Zein nanoparticles produced by liquid-liquid dispersion.
Food Hydrocolloids 2009, 23:2380–2387.
52. Jiang Q, Yang Y: Water-stable electrospun zein fibers for potential drug
delivery. J Biomater Sci Polym Ed 2011, 22:1393–1408.
53. Gennadios A, Weller CL: Moisture adsorption by grain protein films.
Trans ASAE 1994, 37:535–539.
54. Everett DH: Basic Principles of Colloid Science. London: Royal Society of
Chemistry; 1988.
55. O'Hagan DT: The intestinal uptake of particles and the implications for
drug and antigen delivery. J Anat 1996, 189:477–482.
56. Clark MA, Jepson MA, Hirst BH: Exploiting M cells for drug and vaccine
delivery. Adv Drug Deliv Rev 2001, 50:81–106.
57. Hombach J, Bernkop-Schnurch A: Handbook of experimental
pharmacology. Handb Exp Pharmacol 2010, 197:251–266.
58. Astete CE, Sabliov CM: Synthesis and characterization of PLGA
nanoparticles. J Biomater Sci Polym Ed 2006, 17:247–289.
59. Mao H-Q, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, August JT, Leong
KW: Chitosan-DNA nanoparticles as gene carriers: synthesis
characterization and transfection efficiency. J Control Release 2001,
70:399–421.
60. Masotti A, Bordi F, Ortaggi G, Marino F, Palocci C: A novel method to
obtain chitosan/DNA nanospheres and a study of their release
properties. Nanotechnology 2008, 19:055302.
61. Jang J-H, Shea LD: Controllable delivery of non-viral DNA from porous
scaffolds. J Control Release 2003, 86:157–168.
62. Luo Y, Zhang B, Whent M, Yu L, Wang Q: Preparation and characterization
of zein/chitosan complex for encapsulation of α-tocopherol, and its
in vitro controlled release study. Colloids Surf B Biointerfaces 2011,
85:145–152.
63. Podaralla S, Perumal O: Preparation of Zein Nanoparticles by pH
Controlled Nanoprecipitation. J Biomed Nanotechnol 2010, 6:312–317.
64. Lawton JW: Zein: A History of Processing and Use. Cereal Chemistry 2002,
79:1–18.
65. Gong S, Wang H, Sun Q-S, Xue S-T, Wang J-Y: Mechanical properties and
in vitro biocompatibility of porous zein scaffolds. Biomaterials 2006,
27:3793–3799.
66. Mathiowitz E, Bernstein H, Morrel E, Schwaller K: Method for producing
protein microspheres., . Patent US ed., vol. 5,271,961; 1993.
67. Gan Q, Wang T, Cochrane C, McCarron P: Modulation of surface charge,
particle size and morphological properties of chitosan–TPP nanoparticles
intended for gene delivery. Colloids Surf B Biointerfaces 2005, 44:65–73.
68. Demetriades K, Coupland JN, McClements DJ: Physical Properties of Whey
Protein Stabilized Emulsions as Related to pH and NaCl. J Food Sci 1997,
62:342–347.
69. Lai LF, Guo HX: Preparation of new 5-fluorouracil-loaded zein
nanoparticles for liver targeting. Int J Pharm 2011, 404:317–323.
doi:10.1186/1477-3155-10-44
Cite this article as: Regier et al.: Fabrication and characterization of
DNA-loaded zein nanospheres. Journal of Nanobiotechnology 2012 10:44.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Regier et al. Journal of Nanobiotechnology 2012, 10:44 Page 13 of 13
http://www.jnanobiotechnology.com/content/10/1/44
